tiprankstipranks
Advertisement
Advertisement

AQST Stock Latest News

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 
Class ActionAquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 
11d ago
AQST
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting
PremiumCompany Announcements
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting
12d ago
8K
AQST
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
PremiumThe Fly
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
12d ago
AQST
Aquestive Therapeutics Announces Key Legal Leadership Transition
PremiumCompany Announcements
Aquestive Therapeutics Announces Key Legal Leadership Transition
22d ago
8K
AQST
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
PremiumThe Fly
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
22d ago
AQST
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
PremiumClass ActionAquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
24d ago
AQST
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
Premium
Ratings
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
1M ago
AQST
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
Premium
Company Announcements
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
1M ago
AQST
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
PremiumCompany Announcements
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
1M ago
AQST
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
PremiumThe Fly
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
1M ago
AQST
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
PremiumCompany Announcements
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
1M ago
8K
AQST
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
PremiumThe Fly
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
1M ago
AQST
Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
PremiumThe FlyAquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
1M ago
AQST
Aquestive Therapeutics options imply 4.2% move in share price post-earnings
Premium
The Fly
Aquestive Therapeutics options imply 4.2% move in share price post-earnings
1M ago
AQST
AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
AQST
Aquestive Highlights Strategy, Pipeline and Risk Disclosures
PremiumCompany Announcements
Aquestive Highlights Strategy, Pipeline and Risk Disclosures
1M ago
8K
AQST
Aquestive announces poster presentations on Anaphylm at AAAAI meeting
PremiumThe Fly
Aquestive announces poster presentations on Anaphylm at AAAAI meeting
2M ago
AQST
Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
PremiumRatings
Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
2M ago
AQST
Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer
PremiumThe Fly
Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer
2M ago
AQST
Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street
PremiumThe FlyAquestive Therapeutics price target lowered to $6 from $8 at Lake Street
2M ago
AQST
Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline
Premium
Ratings
Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline
2M ago
AQST
Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval
Premium
Ratings
Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval
2M ago
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >